Clinical trial
A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea
NCT06113198 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- November 10, 2023
- Completion date
- February 8, 2027
- Enrollment
- 50 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.